At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 417 enrolled
Drug / intervention
Ixekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab, Placebo, and 1 other intervention for Psoriasis, Arthritic. Completed, enrolled 417 participants across 116 sites in 15 countries.
Detailed Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Arthritic
CountriesBelgium, Bulgaria, Canada, Czechia, Estonia, France, Japan, Mexico, Netherlands, Poland, Russia, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartDec 2012
Primary CompletionDec 2014
Study CompletionSep 2017
TodayJul 2026
First PostedSep 27, 2012
Enrollment StartDec 1, 2012
Primary CompletionDec 1, 2014
Study CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.8 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC
Adalimumabdrug
Administered SC